Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096629 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Kidney Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00096629: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00096629 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096629, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
Interventions
- BIOLOGICAL human prostate-specific membrane antigen plasmid DNA vaccine
- BIOLOGICAL mouse prostate-specific membrane antigen plasmid DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096629
The ClinicalTrials.gov registry entry for NCT00096629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which human prostate-specific membrane antigen plasmid DNA vaccine is the first listed.
NCT00096629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096629 about?
NCT00096629 is a clinical study titled "Vaccine Therapy in Treating Patients With Kidney Cancer". RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
What is the current status of trial NCT00096629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT00096629?
The interventions under investigation include: human prostate-specific membrane antigen plasmid DNA vaccine (BIOLOGICAL), mouse prostate-specific membrane antigen plasmid DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00096629?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.